Avelumab and Merkel Cell Carcinoma: A Review of the Evidence

Legacy Framework for Structured Data Collection

Building on established frameworks for aggregating institutional data across scientific domains, the legacy approach systematically cataloged university departments, observatory databases, and grant-funded projects to map research infrastructure. This methodology prioritized structured extraction of entity attributes—such as institution type, geographic coordinates, and equipment specifications—to enable comparative analysis and resource allocation. The same principle of structured data collection can be applied to occupational exposure monitoring in industrial settings. In mass production environments, where workers may encounter chemical agents during manufacturing processes, systematic tracking of exposure incidents becomes critical. Transitioning from general health science information gathering to targeted occupational surveillance, the focus shifts to documenting exposure events, agent characteristics, and workforce demographics. This pivot requires adapting the legacy data schema to capture exposure contexts—such as duration, concentration levels, and protective measures—rather than equipment lists or grant statuses. The core matrix of location, entity type, and status remains relevant, but the entity type now refers to production facilities or job roles, and the status field tracks exposure frequency or mitigation actions. This evolution from academic resource mapping to occupational health monitoring preserves the neutral, structured approach while addressing workplace safety concerns.

Bridging to Avelumab and Merkel Cell Carcinoma

Applying this structured approach to pharmacovigilance, we now examine the relationship between avelumab (Bavencio) and Merkel cell carcinoma (MCC). Avelumab is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic MCC, a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab was the first therapeutic agent specifically approved for this indication, and its approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). In Europe, approved systemic therapies for metastatic MCC are limited to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/).

Mechanisms and Evidence: Avelumab as Treatment, Not Cause

Merkel cell carcinoma has a rising incidence and high mortality. Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment of metastatic MCC involves anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which, compared with conventional chemotherapy, show better overall response rates and longer duration of responses (https://pubmed.ncbi.nlm.nih.gov/34445385/). However, approximately 50% of patients do not respond or develop immune-related adverse events (irAEs) due to diverse mechanisms, including down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Regarding mechanistic pathways linking avelumab to Merkel cell carcinoma, the drug is used as a treatment for MCC, not as a cause. The evidence indicates that avelumab is an approved therapy for metastatic MCC, and its mechanism involves blocking PD-L1 to enhance anti-tumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). There is no evidence in the provided snippets suggesting that avelumab exposure causes Merkel cell carcinoma. Instead, the literature focuses on avelumab's role in treating MCC and managing refractory cases. For instance, a study of avelumab-refractory MCC patients treated with combined ipilimumab plus nivolumab at three German sites found that three out of five patients responded to the combination therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Risk Considerations and Clinical Context

Risk considerations for affected patients include the adequacy of warnings regarding avelumab and Merkel cell carcinoma. The evidence does not indicate that avelumab causes MCC; rather, it is a standard treatment. Therefore, warnings would appropriately address its use as a therapy, including potential irAEs and the possibility of non-response or progression. For patients who experience avelumab-refractory disease, alternative treatments such as combined ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The timeline between avelumab exposure and documented harm is not directly addressed in the provided snippets, but the literature describes treatment courses and outcomes, including response rates and irAE management, without suggesting a causal link to MCC development. In summary, the evidence supports that avelumab is an effective treatment for metastatic Merkel cell carcinoma, with no data indicating that it causes the disease. Causation-related considerations should focus on the drug's therapeutic role and potential adverse effects, rather than a causal relationship with MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence indicates that avelumab is an approved treatment for metastatic Merkel cell carcinoma (MCC), not a cause. Avelumab works by blocking PD-L1 to enhance anti-tumor immune responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). There is no data suggesting that avelumab exposure leads to the development of MCC.

What are the common side effects of avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These may include conditions like hypercalcaemia secondary to sarcoidosis reactivation, which can be managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). Approximately 50% of patients may not respond or develop irAEs (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.